METASTATIC RENAL CELL CARCINOMA

This study is testing a different way of taking the drug cabozantinib to see if it can reduce severe side effects while still controlling cancer growth. It involves 111 adults with advanced kidney cancer or neuroendocrine tumors. The goal is to find a dosing schedule that patient…

This study tests whether a ketogenic (low-carb, high-fat) diet can make immunotherapy more effective for people with advanced melanoma or kidney cancer. About 60 adults will follow the diet while receiving standard immunotherapy drugs. The main goals are to see if the diet is saf…

This study tests a daily pill called olaparib in people with advanced kidney cancer that has certain gene mutations (like BAP-1 or BRCA). The goal is to see if the drug can shrink tumors or keep them stable for at least six months. About 20 adults who have already tried other tre…

This study tests a new medicine, PF-08634404, for adults with advanced kidney cancer that has spread. The goal is to see if the drug, given alone or with other cancer treatments, can shrink tumors and is safe. Participants must not have had prior treatment for their advanced canc…

This study is for people with kidney cancer that has spread to other parts of the body. It compares two standard treatments: immunotherapy drugs alone versus immunotherapy plus surgery to remove the affected kidney. The goal is to see if adding surgery helps people live longer. A…

This study looks at whether having patients report their symptoms weekly through a digital app helps doctors make better treatment decisions. It involves 83 adults with advanced kidney cancer who are starting a combination of two drugs (cabozantinib and nivolumab). The goal is to…

This study tests whether giving focused radiation to a few growing cancer spots can help people with advanced kidney cancer stay on their current immunotherapy longer. About 30 adults whose cancer has progressed in 1 to 5 spots while on immunotherapy will receive radiation to tho…

This study tests whether combining two drugs, abemaciclib and cabozantinib, is safe and works for people with advanced kidney cancer that has spread. About 43 adults whose cancer did not respond to immunotherapy will receive different doses to find the best one with fewest side e…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…

This study tests a new drug (zanzalintinib) alone or with an immunotherapy (nivolumab) in 70 adults with advanced kidney cancer that worsened after standard initial treatment. The goal is to see if the combination shrinks tumors better than the drug alone. Participants will take …

This study tests whether combining two drugs—pembrolizumab (an immunotherapy) and aldesleukin (a cytokine)—can shrink tumors in people with advanced melanoma or kidney cancer that has not responded to prior treatments. About 78 adults will receive the drugs through an IV during t…

This early-phase study tests a wearable device that creates low-intensity electric fields (tumor treating fields) combined with either cabozantinib or a chemo-immunotherapy pair (nab-paclitaxel and atezolizumab) in people with advanced solid tumors in the abdomen or chest. The go…

This study is testing whether a combination of three drugs—sasanlimab, palbociclib, and axitinib—can shrink or control advanced kidney cancer that has spread. About 25 adults with clear cell or translocation renal cell carcinoma will receive the drugs and be monitored for tumor r…

This study is for people with advanced kidney cancer that has spread and cannot be removed by surgery. It tests whether adding a precise, high-dose form of radiation (SABR) to the main tumor, alongside standard immunotherapy drugs, can better control the cancer and delay its grow…

This study is for people with kidney cancer that has spread to a few places and is starting to grow again despite current treatment. Instead of switching to a new drug right away, doctors will use precise, high-dose radiation on the growing spots. The goal is to control those spo…

This study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers believe the body's internal clock (circadian rhythm) might affect immune response. About 160 adults with certain cancers like …

This study tests whether giving radiation in three smaller doses (fractionated SRS) is better than a single large dose (standard SRS) for treating cancer that has spread to the brain. About 269 adults with certain cancers (like lung, breast, or melanoma) will be enrolled. The goa…

This study tests whether freezing bone tumors (cryoablation) before giving radiation therapy works better than radiation alone for reducing pain. About 40 adults with cancer that has spread to the bones will be enrolled. The goal is to see if the combination provides more complet…